Gotham City Capital
Healthcare, biotech, mid-cap, small-cap

Previous Data Signals Positive Phase IIb Results Likely To Come For Synergy Pharmaceuticals

Written by Travis Knight

All eyes are once again on Synergy Pharmaceuticals (NASDAQ:SGYP) in anticipation of Phase IIb data to be released regarding its 350-patient study, evaluating patients with IBS-C (irritable bowel syndrome with constipation). The company expects completion of the study by April, with topline Phase IIb data to follow shortly afterwards. In December, enrollment was closed for this study and the company guided that data would be released at the beginning of the second quarter, a bit later than initially guided. A sell-off in share price following the news has given investors the opportunity to grab shares at a really good price. With increasing confidence in plecanatide based on previous data studying patients with a...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details